| Symbol | CURX |
|---|---|
| Name | CURANEX PHARMACEUTICALS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2 JERICHO PLAZA,SUITE 101B, JERICHO, New York, 11753, United States |
| Telephone | 718-673-6078 |
| Fax | — |
| — | |
| Website | www.curanexpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002025942 |
| Description | Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Additional info from NASDAQ: |
Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX
Read moreRosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX
Read moreCuranex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline
Read moreCuranex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care
Read more(89% Positive) CURANEX PHARMACEUTICALS INC (CURX) Announces Clinical Development Update
Read moreCuranex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company
Read moreCuranex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission
Read moreNew Form 10-K - Curanex Pharmaceuticals Inc <b>Filed:</b> 2026-03-30 <b>AccNo:</b> 0001493152-26-013677 <b>Size:</b> 18 MB
Read moreCuranex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission
Read moreCuranex Expands Scientific Advisory Board With Two Distinguished Researchers
Read more